Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness (ANOWSM)

7. srpna 2026 aktualizováno: Shachi Tyagi, University of Pittsburgh

The goal of this clinical trial is to examine and compare the effect of behavioral sleep treatment: BBTI (brief behavioral treatment of insomnia) and brief mindfulness (MI), independently and combined vs control on frequency of nighttime awakenings to void (nocturia) and on nighttime urine production in older women over the age 65 years with nocturia.

To study the effect of these treatments, participants will be randomly assigned to one of the following groups 1) BBTI alone, 2) MI alone, 3) BBTI+MI, or 4) control: sleep information only without any structured sleep or mindfulness therapy.

The study aims to examine the effect of these therapies at end-of-treatment (week 4), as well sustained effects at 3- and 6-months. The main questions the study aims to answer are:

  1. do these treatments reduce the frequency of nighttime awakenings to void
  2. do these treatments reduce the volume of nighttime urine production
  3. do these treatments improve sleep quality

Frequency of nocturia and sleep quality will be assessed via questionnaires and nighttime urine volume using bladder-sleep diaries which is 3-day record participants will complete at home documenting every time they go to the bathroom and volume they voided. In addition, sleep and sleep interruptions will also be assessed using an FDA-cleared home sleep testing device called Zmachine®.

Přehled studie

Detailní popis

Nocturia, or waking at night to void, and poor sleep are prevalent and comorbid conditions in the elderly. Nocturia affects up to 70% of those over age 60, and over 75% of the older adults with poor sleep report nocturia as the main reason. Nocturia increases risk for falls, fractures, depression, institutionalization, and death. Poor sleep and nocturia have a bidirectional relationship and are mutually exacerbating. Nocturnal polyuria (NP) or excess urine production during sleep is the major contributor to nocturia in the elderly and poor sleep is known to cause NP. Vasopressin and aldosterone peak during sleep, causing sodium and water reabsorption in renal tubuli, which leads to decrease in nighttime urine production. Sleep loss leads to attenuation of the sleep time release of these hormones, resulting in natriuresis and diuresis causing NP.

Brief behavioral treatment of insomnia (BBTI- a brief 4-week, efficacious behavioral treatment for insomnia) is effective in addressing sleep and nocturia. Investigators found in their recently concluded pilot trial among older adults with comorbid nocturia (≥2/night) and poor sleep, that BBTI improved nocturia more than control (-0.9 vs -0.3, p=.016). Compared to control, BBTI improved subjective insomnia severity index (-5.9 vs -2.5, p=.02). Additionally, BBTI also improved NP: % of 24h urine volume excreted at night decreased in BBTI vs control (-7.1±13%, p=.001 vs -4±11, p=.08). Although BBTI is brief and effective for nocturia, adherence to behavioral sleep treatments among patients with chronic conditions (poor sleep, nocturia) is disappointingly low compared to patients with acute conditions, particularly several months after therapy. Moreover, the time and personnel needed to train professionals and to administer the intervention has limited the scalability of this otherwise promising treatment. Alternatives to boost treatment adherence and maintain benefit need to be investigated.

Recently the investigators trialed brief mindfulness (MI) training alone or paired with transcranial direct current stimulation (tDCS) in older women with urinary incontinence to enhance cognitive control over bladder symptoms. Of these women, those who had nocturia (≥1/night) and received MI training alone experienced improvement in nocturia (-0.5±0.6, p=0.005) with a concurrent increase in FUSP (39.8±70.2 minutes, p=0.02). Interestingly, effect of MI on nocturia and FUSP were similar to that seen with BBTI. MI requires only brief training followed by convenient at-home use. It was well liked in our study with an acceptability of 85.6 and compliance of 94.4 on a 1-100 Likert scale indicating MI may be a simpler and scalable modality either alone or to augment BBTI for reducing nocturia in older women.

This study a randomized pilot trial in older women with interrupted sleep due to nocturia to examine the effect of BBTI and MI on nocturia, nighttime urine production, and sleep quality at 4-week (post-intervention) and 3- and 6-months later. The investigators postulate that both interventions, individually and in combination, will be beneficial, and the combined treatment will lead to sustained treatment effects at 3- and 6-months.

The study will include older women with nocturia. Sleep will be assessed subjectively with the Pittsburgh Sleep Quality Index (PSQI) and objectively using Zmachine®, an FDA cleared in-home single channel EEG device, and a 3-day bladder-sleep diary that concurrently assesses sleep and voiding pattern including frequency and volume during day and night. Participants will be randomized to one of the 4 groups in a 2x2 factorial design: i) BBTI, ii) MI, iii) BBTI+MI or iv) control. Participants will repeat the study measures at 4 weeks, and 3- and 6-months.

The study aims to explore the effects of MI and BBTI. Hypothesis: Compared to control, BBTI and/or MI groups will result in greater improvement in 1) nocturia, 2) volume of nighttime urine volume, and 3) sleep quality at 4 weeks with the combined BBTI+MI intervention conferring greater benefits and sustained treatment effects at 3- and 6-months.

This study will be the first RCT to evaluate the effect of BBTI and MI, individually and combined on nocturia and sleep, and to assess durability of benefit. The results will provide novel information regarding the promise of efficient cost-effective, and easy to disseminate means of treating nocturia in older women and facilitate confirmatory trial to provide definitive evidence and develop clinically acceptable treatment protocols.

Typ studie

Intervenční

Zápis (Odhadovaný)

80

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Shachi Tyagi, MD, MS
  • Telefonní číslo: 14126471274
  • E-mail: sht55@pitt.edu

Studijní záloha kontaktů

  • Jméno: Becky D Clarkson, PhD
  • Telefonní číslo: 4126471270
  • E-mail: bdc29@pitt.edu

Studijní místa

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Spojené státy, 15213
        • University of Pittsburgh
        • Kontakt:
          • Shachi Tyagi, MD, MS
          • Telefonní číslo: 412-647-1274
          • E-mail: sht55@pitt.edu
        • Kontakt:
          • Becky D Clarkson, PhD
          • Telefonní číslo: 412.647.1270
          • E-mail: bdc29@pitt.edu

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Female
  • Age > or =65 years
  • Nocturia ≥2/night
  • Poor sleep (Insomnia Severity Index ≥8)
  • MoCA (including trail making) >26

Exclusion Criteria:

  • Conditions that affect bladder function: Multiple sclerosis, Alzheimer's disease, spinal cord injury, urethral obstruction, urinary retention, interstitial cystitis, bladder cancer, radiation to the pelvic area, bladder surgery, current or uncontrolled chronic or recurrent bowel issues, bacterial endocarditis
  • cardiac or respiratory disease that limits daily function
  • Unstable or acute medical condition:

    - Any acute medical condition that requires immediate treatment such that it would interfere with the study protocol; Each instance will be assessed on a case-by-case basis by our study physician who may postpone a participant's enrollment; stably managed chronic conditions are exempt from this exclusion.

  • Untreated, current, severe psychiatric condition (assessed during Visit 1a- medical history)
  • Post void residual ≥ 200ml- assessed during baseline visit
  • Currently diagnosed and/or untreated obstructive sleep apnea, untreated restless leg syndrome, untreated parasomnia
  • Untreated or poorly controlled fluid overload conditions like CHF, diabetes

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Singl

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Jiný: Řízení
The control condition is intended to emulate the behavioral treatment information generally available to patients.
Experimentální: BBTI
Brief behavioral treatment of insomnia

BBTI: will entail a 45- to 60-minute individual intervention session with instructions regarding sleep education and discussion of homeostatic and circadian mechanisms of human sleep regulation. This education provides the rationale for the 4 main interventions of BBTI:

  1. reduce time in bed;
  2. get up at the same time every day, regardless of sleep duration;
  3. do not go to bed unless sleepy; and
  4. do not stay in bed unless asleep
Experimentální: MI
Brief mindfulness
Participants in the MI group will be trained to engage in a brief mindfulness method involving body scan with acceptance language training.
Experimentální: BBTI+MI
Brief behavioral treatment of insomnia and brief mindfulness
Participants in this arm will receive BBTI as well as MI training.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Nocturia
Časové okno: 4 weeks, 3- and 6-months post-intervention
number of nighttime awakenings to void
4 weeks, 3- and 6-months post-intervention

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Nocturnal polyuria index (NPi)
Časové okno: 4 weeks, 3- and 6-months post-intervention
percentage of 24-hour urine volume excreted at night
4 weeks, 3- and 6-months post-intervention
Pittsburgh Sleep Quality Index (PSQI)
Časové okno: 4-weeks, 3- and 6-month post intervention
Self-reported sleep quality questionnaire scored by grouping 19 self-rated questions into seven component scores, summing them into a global score (0 to 21)> PSQI score >5 Indicates significant, poor sleep quality and clinical sleep disturbance.
4-weeks, 3- and 6-month post intervention

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Shachi Tyagi, MD, MS, University of Pittsburgh
  • Studijní židle: Shachi Tyagi, MD, MS, University of Pittsburgh
  • Ředitel studie: Becky D Clarkson, PhD, University of Pittsburgh

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

15. září 2026

Primární dokončení (Odhadovaný)

30. října 2028

Dokončení studie (Odhadovaný)

30. dubna 2029

Termíny zápisu do studia

První předloženo

7. srpna 2026

První předloženo, které splnilo kritéria kontroly kvality

7. srpna 2026

První zveřejněno (Aktuální)

12. srpna 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

12. srpna 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

7. srpna 2026

Naposledy ověřeno

1. srpna 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

All of the individual participant data collected during the trial, after deidentification may be shared with other researchers.

Časový rámec sdílení IPD

Following publication, no end date

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • ICF
  • CSR

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit